SCHEMBL16084958

SCHEMBL16084958

Cc1ccc(CCN2C(=O)NC(Cc3c[nH]c4c(Cl)cccc34)C2=O)cc1C#Cc1cnc2cccnn12

nearest known ligand 0.92

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 5/20 0.92
RIPK2 O43353 1/20 0.92
RIPK3 Q9Y572 1/20 0.92
TNF P01375 5/20 0.47
ABL1 P00519 7/20 0.40
CYP3A4 P08684 4/20 0.39
KCNH2 Q12809 4/20 0.39
LCK P06239 2/20 0.37
SRC P12931 2/20 0.37
PDGFRA P16234 2/20 0.37
EPHB2 P29323 2/20 0.37
EPHB3 P54753 2/20 0.37
EPHB4 P54760 2/20 0.37
NEK6 Q9HC98 2/20 0.37
DDR2 Q16832 1/20 0.37
MAP4K3 Q8IVH8 1/20 0.37
ROR1 Q01973 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17471719 0.97 RIPK1 (0.99) RIPK1RIPK2RIPK3TNFABL1
SCHEMBL29686895 0.96 RIPK1 (1.00) RIPK1RIPK2RIPK3TNFABL1
SCHEMBL21678896 0.96 RIPK1 (1.00) RIPK1RIPK2RIPK3TNFABL1
SCHEMBL29353518 0.96 RIPK1 (1.00) RIPK1RIPK2RIPK3TNFABL1
SCHEMBL16084942 0.96 RIPK1 (1.00) RIPK1RIPK2RIPK3TNFABL1
SCHEMBL17471690 0.95 RIPK1 (0.99) RIPK1RIPK2RIPK3TNFABL1
SCHEMBL16084944 0.91 RIPK1 (0.90) RIPK1RIPK2RIPK3TNFABL1
SCHEMBL16084949 0.90 RIPK1 (0.79) RIPK1RIPK2RIPK3TNFABL1
SCHEMBL16084948 0.90 RIPK1 (0.79) RIPK1RIPK2RIPK3TNFABL1
SCHEMBL16084969 0.87 RIPK1 (0.75) RIPK1RIPK2RIPK3ABL1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160024098-A1 HYBRID NECROPTOSIS INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-01-28 US disclosed
US-20160024098-A1 HYBRID NECROPTOSIS INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-01-28 US disclosed
WO-2014145022-A1 HYBRID NECROPTOSIS INHIBITORS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2014-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160024098-A1 HYBRID NECROPTOSIS INHIBITORS RIPK3, RIPK1, RIPK4 RIPK1 2/4885RIPK2 4/4885RIPK3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.